CHRONIC GRAFT-VERSUS-HOST-DISEASE

This study tests a new oral drug called alvelestat (MPH966) in adults who have lung damage (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block an enzyme that may cause lung injury. The trial has two parts: first to find the safest and most eff…

This Phase 2 trial tests whether adding axatilimab to the standard drug ruxolitinib works better for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 130 participants aged 12 and older will …

This study tests a new drug called axatilimab against the best current treatments for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants must be at least 12 years old and have tried at least two prior treatments withou…

This phase 2 trial tests whether daily low-dose injections of interleukin-2 (IL-2) can help control chronic graft-versus-host disease (cGVHD) in 35 people who did not respond to steroids. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack t…

This study aimed to test the safety and effectiveness of the oral drug belumosudil in Black, Native American, and Pacific Islander patients aged 12 and older with chronic graft-versus-host disease (cGVHD) who had already tried at least two other treatments. The goal was to see if…

This early-phase trial tests the safety of combining donor anti-inflammatory Treg cells with low-dose Interleukin-2 (IL-2) for people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a complication after a stem cell or bone marrow transpl…

This study tests a drug called axatilimab in Japanese patients with chronic graft-versus-host disease (cGVHD) that has not improved after at least two prior treatments. cGVHD is a complication of stem cell transplants where donor cells attack the patient's body. The goal is to se…

This study tests a new tablet called TQ05105 in 45 adults with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. The drug works by blocking a protein pathway involved in inflammation. The goal is to find the right dose and see if it c…

This early-phase study tests a new treatment called CD6-CAR Tregs for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The treatment uses specially engineered immune cells from a donor to help control the immune attack on the pat…

This study tests whether adding the drug belumosudil to standard steroids helps control chronic graft-versus-host disease (cGVHD) better than steroids alone. cGVHD is a serious condition where donor immune cells attack the recipient's body after a stem cell transplant. About 260 …

This study tests whether a group-based behavioral program called Horizons can improve quality of life and coping skills in adults with chronic graft-versus-host disease (cGVHD), a common complication after stem cell transplant. The program involves 8 weekly video sessions with a …

This study tests whether a telehealth palliative care program is practical and well-liked by people with moderate to severe chronic graft-versus-host disease (cGVHD), a long-term complication after a stem cell transplant. Ten adults will receive up to three video-based palliative…

This study is testing whether a mobile app called Horizons can help adults with chronic graft-versus-host disease (a long-term complication after a bone marrow transplant) manage their symptoms and improve their quality of life. Twenty participants will use the app for about six …

This study tests a telehealth program called Horizons for adults who have had a stem cell transplant and developed moderate to severe chronic graft-versus-host disease (GVHD). The program uses video sessions and questionnaires to help patients cope and follow their treatment plan…

This study tests a mobile app called Horizons designed to help people with chronic graft-versus-host disease (GVHD) after a stem cell transplant. The app aims to improve quality of life, reduce symptoms, and support coping. About 120 adults with moderate to severe chronic GVHD wi…

This study aims to create a symptom questionnaire specifically for children and teens living with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Current symptom scales are designed for adults, but children may describe their symptoms differently. Research…

This study looks at whether new guidelines from the National Institutes of Health can help doctors better diagnose and track chronic graft-versus-host disease (GVHD), a common complication after stem cell transplants. Researchers are following 601 patients over several years, col…

This study involves 383 people who have chronic graft-versus-host disease (GVHD) after a stem cell transplant. Researchers are developing and testing new ways to measure whether a treatment is working, including a symptom-based activity index and a score that predicts long-term s…

This study looks at how different types of immune cells in the skin, called dendritic cells, are involved in graft-versus-host disease (GVHD) after a bone marrow transplant. Researchers will take small skin samples and blood from 22 adults with acute or chronic skin GVHD. The goa…